The 3,600 sqft facility will help develop the MIMIX sustained-release intradermal microneedle patch, which is planned for proof-of-concept trials for COVID-19 in 2022
The #1 conference is back with this year’s edition shaping up to be the most consequential yet with deeper technical insight, sharper conversations and a renewed focus on the...
Get breaking news, product releases, technical papers, innovation features, trend reports and live content agendas covering the entire industry.